Laurus Labs gets EIR from USFDA for two API plants in Vizag

3

Both the units that manufacture active pharmaceutical ingredients (API) were inspected by US FDA in August 2017 and got two observations which were of procedural in nature.

Drug maker Laurus Labs  said it has received Establishment Inspection Report (EIR) from US FDA for its Unit 1 and Unit 3 plants located at Parawada, Visakhapatnam.

EIR indicates the closure of inspection.

Both the units that manufacture active pharmaceutical ingredients (API) were inspected by US FDA in August 2017 and got two observations which were of procedural in nature.

Laurus is one of the world’s largest suppliers of APIs for antiretroviral and Hepatitis-C drugs, and works with most of the top generic companies.

Shares of Laurus gained 0.01 percent to close at Rs 524.30 on BSE, while the benchmark Sensex declined 0.28 percent to end at 32,941.87 points.

Source-moneycontrol.com

Published on:


Address

Gubba Cold Storage


Plot No-25, Near RTA Office, P&T Colony, Tirumalagiri, Secunderabad 500015

+91 - 8008212626

support@gubbagroup.com

www.gubbagroup.com


Gubba Cold Storages in India